Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CsA-PG Ophthalmic Gel in Dry Eye Patients
NCT06942793Phase 3Not yet recruiting
- Sponsor
- Zhaoke Ophthalmology
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of cyclosporine 2% ophthalmic solution in dry eye disease (DED) (2 arms), sponsored by Zhaoke Ophthalmology. Primary endpoint: Eye Dryness Score at 84 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06942793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942793.